170 related articles for article (PubMed ID: 36346502)
21. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
22. Theranostic role of radiolabelled RGD peptide in the treatment of radioiodine-resistant thyroid cancer: A novel agent.
Vatsa R; Sood A
Indian J Med Res; 2020 Nov; 152(Suppl 1):S258-S259. PubMed ID: 35345242
[No Abstract] [Full Text] [Related]
23. Joint EANM, SNMMI and IAEA enabling guide: how to set up a theranostics centre.
Herrmann K; Giovanella L; Santos A; Gear J; Kiratli PO; Kurth J; Denis-Bacelar AM; Hustinx R; Patt M; Wahl RL; Paez D; Giammarile F; Jadvar H; Pandit-Taskar N; Ghesani M; Kunikowska J
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2300-2309. PubMed ID: 35403861
[TBL] [Abstract][Full Text] [Related]
24. A Review of the History of Radioactive Iodine Theranostics: The Origin of Nuclear Ontology.
Ehrhardt JD; Güleç S
Mol Imaging Radionucl Ther; 2020 Oct; 29(3):88-97. PubMed ID: 33094571
[TBL] [Abstract][Full Text] [Related]
25. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets.
Spitzweg C; Bible KC; Hofbauer LC; Morris JC
Lancet Diabetes Endocrinol; 2014 Oct; 2(10):830-42. PubMed ID: 24898835
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
[TBL] [Abstract][Full Text] [Related]
27. Lu-177 labelled peptide treatment for radioiodine refractory differentiated thyroid carcinoma.
Elboğa U; Özkaya M; Sayiner ZA; Çelen YZ
BMJ Case Rep; 2016 Mar; 2016():. PubMed ID: 26957032
[TBL] [Abstract][Full Text] [Related]
28. Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
Herrmann K; Giovanella L; Santos A; Gear J; Ozgen Kiratli P; Kurth J; Denis-Bacelar AM; Hustinx R; Patt M; Wahl RL; Paez D; Giammarile F; Jadvar H; Pandit-Taskar N; Ghesani M; Kunikowska J
J Nucl Med; 2022 Dec; 63(12):1836-1843. PubMed ID: 35450957
[TBL] [Abstract][Full Text] [Related]
29. [Oncological theranostics in nuclear medicine].
Laschinsky C; Herrmann K; Fendler W; Nader M; Lahner H; Hadaschik B; Sandach P
Radiologie (Heidelb); 2022 Oct; 62(10):875-884. PubMed ID: 36112174
[TBL] [Abstract][Full Text] [Related]
30. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
31. Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead.
Satapathy S; Bal C
Front Endocrinol (Lausanne); 2022; 13():924841. PubMed ID: 35903277
[TBL] [Abstract][Full Text] [Related]
32. PSMA Expression in Differentiated Thyroid Cancer: Association With Radioiodine, 18FDG Uptake, and Patient Outcome.
Ciappuccini R; Saguet-Rysanek V; Giffard F; Licaj I; Dorbeau M; Clarisse B; Poulain L; Bardet S
J Clin Endocrinol Metab; 2021 Nov; 106(12):3536-3545. PubMed ID: 34331544
[TBL] [Abstract][Full Text] [Related]
33. Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond.
Bulotta S; Celano M; Costante G; Russo D
Curr Opin Oncol; 2020 Jan; 32(1):13-19. PubMed ID: 31599772
[TBL] [Abstract][Full Text] [Related]
34. Modeling therapeutic response to radioiodine in metastatic thyroid cancer: a proof-of-concept study for individualized medicine.
Barbolosi D; Summer I; Meille C; Serre R; Kelly A; Zerdoud S; Bournaud C; Schvartz C; Toubeau M; Toubert ME; Keller I; Taïeb D
Oncotarget; 2017 Jun; 8(24):39167-39176. PubMed ID: 28389624
[TBL] [Abstract][Full Text] [Related]
35. Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis.
Budiawan H; Salavati A; Kulkarni HR; Baum RP
Am J Nucl Med Mol Imaging; 2013; 4(1):39-52. PubMed ID: 24380044
[TBL] [Abstract][Full Text] [Related]
36. The utility of radioiodine scans prior to iodine 131 ablation in patients with well-differentiated thyroid cancer.
Van Nostrand D; Aiken M; Atkins F; Moreau S; Garcia C; Acio E; Burman K; Wartofsky L
Thyroid; 2009 Aug; 19(8):849-55. PubMed ID: 19281428
[TBL] [Abstract][Full Text] [Related]
37. 99mTc-EDDA/HYNIC-TOC in the diagnosis of differentiated thyroid carcinoma refractory to radioiodine treatment.
Czepczyński R; Gryczyńska M; Ruchała M
Nucl Med Rev Cent East Eur; 2016; 19(2):67-73. PubMed ID: 27479883
[TBL] [Abstract][Full Text] [Related]
38. Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy.
Hasenauer N; Higuchi T; Deschler-Baier B; Hartrampf PE; Pomper MG; Rowe SP; Fassnacht M; Buck AK; Werner RA
Clin Nucl Med; 2022 Jul; 47(7):651-652. PubMed ID: 35085172
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.
Lim DJ; O JH; Kim MH; Kim JH; Kwon HS; Kim SH; Kang MI; Cha BY; Lee KW; Son HY
Korean J Intern Med; 2010 Dec; 25(4):408-14. PubMed ID: 21179279
[TBL] [Abstract][Full Text] [Related]
40. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
